aap Implantate AG / aap reports profitable Q1 2012 sales growth of 51% to EUR 9.9 million; Increased sales forecast for the financial year 2012 to EUR 34 million (+16%) . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
aap Implantate AG, a medical technology company listed in the Frankfurt Stock Exchange's Prime Standard segment, generated EUR 9.9 million in sales (previous year: EUR 6.5 million) in the first three months of financial year 2012, which was a 51% increase on the previous year's first quarter. This strong sales growth was due mainly to an 18% increase in product sales to EUR 7.7 million (previous year: EUR 6.5 million) and to revenue from the conclusion of an exclusive license agreement worth EUR 2.2 million with a world-leading medical technology company. EBITDA increased to EUR 2.1 million (previous year: EUR 0.8 million).
|In EUR million||Q1/2012||Q1/2011||Change|
|In EUR million||3/31/2012||12/31/2011||Change|
|Equity (ratio)||49.4 (74%)||48.4 (73%)||2%|
|Balance sheet total||67.1||66.2||1%|
*Full-Time-Equivalents (FTE) are the number of full-time employed persons during a period
In the first quarter of 2012 aap Group's EBIT was EUR 1.3 million (previous year: EUR 0.1 million) and its EBT amounted to EUR 1.2 million (previous year: EUR 0.1 million). On a balance sheet total of EUR 67.1 million (31.12.2011: EUR 63.4 million) the equity ratio was 74%.
In the first quarter, aap presented its innovative LOQTEQ® product line to potential new distributors in Europe, the United States, Asia and Latin America, while the centre of excellence for trauma in Berlin continued to work on the FDA approval of the LOQTEQ® product family. aap expects to receive full FDA approval on the LOQTEQ® product line in the third quarter of 2012. The center of excellence for contract manufacturing in Nijmegen signed in the first quarter a contract to process human tissue with the Dutch Sanquin bone and tissue bank.
Outlook for 2012
On the basis of the positive result for the first quarter, the current order intake and potential new customer relationships, aap Implantate AG is revising its sales forecast for the financial year 2012. The Management Board now anticipates total sales of around EUR 34 million (previous forecast: around EUR 32 million), or 16% sales growth on the previous year.
The main strategic focus in the financial year 2012 will be on the core business segments trauma and bone cement and cementing techniques, in which aap aims to achieve double-digit sales growth and a positive Cash-EBIT. Sales growth is to be realised through the launch of the innovative LOQTEQ® product line and its FDA approval along with further strong sales growth in the bone cement and cementing techniques segment, license business, OEM contracts and another project deal.
aap Implantate AG's full report for the first quarter of 2012 is available for you to download at www.aap.de (http://www.aap.de/).
This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
aap Implantate AG (ISIN DE0005066609)
- Prime Standard/Regulated Market - All German stock markets -
aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de.
For inquiries please contact:
aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, email@example.com
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: aap Implantate AG via Thomson Reuters ONE
--- End of Message ---
aap Implantate AG
Lorenzweg 5 Berlin Germany
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;